Artificial Intelligence Tool Uses Chest X-ray to Differentiate Worst Cases of COVID-19

What To Know

  • Study senior investigator Krzysztof Geras, PhD, an assistant professor in the Department of Radiology at NYU Langone, says a major advantage to machine-intelligence programs such as theirs is that its accuracy can be tracked, updated and improved with more data.
  • Researchers then tested the predictive value of the software tool on 770 chest X-rays from 718 other patients admitted for COVID-19 through the emergency room at NYU Langone hospitals from March 3 to June 28, 2020.

Trained to see patterns by analyzing thousands of chest X-rays, a computer program predicted with up to 80 percent accuracy which COVID-19 patients would develop life-threatening complications within four days, a new study finds.

Developed by researchers at NYU Grossman School of Medicine, the program used several hundred gigabytes of data gleaned from 5,224 chest X-rays taken from 2,943 seriously ill patients infected with SARS-CoV-2, the virus behind the infections.

The authors of the study, publishing in the journal npj Digital Medicine online May 12, cited the “pressing need” for the ability to quickly predict which COVID-19 patients are likely to have lethal complications so that treatment resources can best be matched to those at increased risk. For reasons not yet fully understood, the health of some COVID-19 patients suddenly worsens, requiring intensive care, and increasing their chances of dying.

In a bid to address this need, the NYU Langone team fed not only X-ray information into their computer analysis, but also patients’ age, race, and gender, along with several vital signs and laboratory test results, including weight, body temperature, and blood immune cell levels. Also factored into their mathematical models, which can learn from examples, were the need for a mechanical ventilator and whether each patient went on to survive (2,405) or die (538) from their infections.

Researchers then tested the predictive value of the software tool on 770 chest X-rays from 718 other patients admitted for COVID-19 through the emergency room at NYU Langone hospitals from March 3 to June 28, 2020. The computer program accurately predicted four out of five infected patients who required intensive care and mechanical ventilation and/or died within four days of admission.

“Emergency room physicians and radiologists need effective tools like our program to quickly identify those COVID-19 patients whose condition is most likely to deteriorate quickly so that health care providers can monitor them more closely and intervene earlier,” says study co-lead investigator Farah Shamout, PhD, an assistant professor in computer engineering at New York University’s campus in Abu Dhabi.

“We believe that our COVID-19 classification test represents the largest application of artificial intelligence in radiology to address some of the most urgent needs of patients and caregivers during the pandemic,” says Yiqiu “Artie” Shen, MS, a doctoral student at the NYU Data Science Center.

Study senior investigator Krzysztof Geras, PhD, an assistant professor in the Department of Radiology at NYU Langone, says a major advantage to machine-intelligence programs such as theirs is that its accuracy can be tracked, updated and improved with more data. He says the team plans to add more patient information as it becomes available. He also says the team is evaluating what additional clinical test results could be used to improve their test model.

Geras says he hopes, as part of further research, to soon deploy the NYU COVID-19 classification test to emergency physicians and radiologists. In the interim, he is working with physicians to draft clinical guidelines for its use.

Funding support for the study was provided by National Institutes of Health grants P41 EB017183 and R01 LM013316; and National Science Foundation grants HDR-1922658 and HDR-1940097.

Besides Geras, Shamout, and Shen, other NYU Langone researchers involved in this study are co-lead investigators Nan Wu; Aakash Kaku; Jungkyu Park; and Taro Makino; and co-investigators Stanislaw Jastrzebski; Duo Wong; Ben Zhang; Siddhant Dogra; Men Cao; Narges Razavian; David Kudlowitz; Lea Azour; William Moore; Yvonne Lui; Yindalon Aphinyanaphongs; and Carlos Fernandez-Granda.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

X-Therma notes this DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.
Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.
"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."
This make it one of the only wearable OTC anti-migraine device that is available without a prescription in the U.S.
NanoDrop has received clearance in the United States as the inaugural blood-lancing device available for over-the-counter use on the upper arm. This development is poised to revolutionize the consumer testing market and decentralized clinical trials within the realm of at-home healthcare.

By using this website you agree to accept Medical Device News Magazine Privacy Policy